COVID-19 Impact on Global Selective Agonists Market Size, Status and Forecast 2020-2026

July 2020 | 153 pages | ID: CD7C33B84445EN
QYResearch

Abstracts

This report focuses on the global Selective Agonists status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Merck
• Bausch Health Companies
• Pfizer
• Sterling Winthrop
• Sanofi
• Paragon BioTeck
• West-Ward Pharmaceuticals
• Biosyent Pharma
• Novartis
• Omega Laboratories
• Medical Purchasing Solutions
• Avadel Legacy Pharmaceuticals
• Amneal Biosciences
• Cipla USA
• Par Pharmaceutical
• Glaxosmithkline
• Teva
• Bayer
• Impax Generics
• Mylan Pharmaceuticals
• Physicians Total Care
• Cadila Pharnmaceuticals
• Alembic Pharmaceuticals
• Allergan
• Mylan

Market segment by Type, the product can be split into

• ?1 Selective Agonists
• ?2 Selective Agonists
• ?1 Selective Agonists
• ?2 Selective Agonists

Market segment by Application, split into

• Paroxysmal Supraventricular Tachycardia
• Eye Drops
• Anaphylaxis
• Cardiac Arrest
• Anaphylaxis
• Cardiac Arrest
• Chronic Heart Failure
• Myocardial Infarction
• Postoperative Hypotension

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Selective Agonists status, future forecast, growth opportunity, key market and key players.
• To present the Selective Agonists development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Selective Agonists are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Selective Agonists Revenue
1.4 Market Analysis by Type
  1.4.1 Global Selective Agonists Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 ?1 Selective Agonists
  1.4.3 ?2 Selective Agonists
  1.4.4 ?1 Selective Agonists
  1.4.5 ?2 Selective Agonists
1.5 Market by Application
  1.5.1 Global Selective Agonists Market Share by Application: 2020 VS 2026
  1.5.2 Paroxysmal Supraventricular Tachycardia
  1.5.3 Eye Drops
  1.5.4 Anaphylaxis
  1.5.5 Cardiac Arrest
  1.5.6 Anaphylaxis
  1.5.7 Cardiac Arrest
  1.5.8 Chronic Heart Failure
  1.5.9 Myocardial Infarction
  1.5.10 Postoperative Hypotension
1.6 Coronavirus Disease 2019 (Covid-19): Selective Agonists Industry Impact
  1.6.1 How the Covid-19 is Affecting the Selective Agonists Industry
    1.6.1.1 Selective Agonists Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Selective Agonists Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Selective Agonists Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Selective Agonists Market Perspective (2015-2026)
2.2 Selective Agonists Growth Trends by Regions
  2.2.1 Selective Agonists Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Selective Agonists Historic Market Share by Regions (2015-2020)
  2.2.3 Selective Agonists Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Selective Agonists Market Growth Strategy
  2.3.6 Primary Interviews with Key Selective Agonists Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Selective Agonists Players by Market Size
  3.1.1 Global Top Selective Agonists Players by Revenue (2015-2020)
  3.1.2 Global Selective Agonists Revenue Market Share by Players (2015-2020)
  3.1.3 Global Selective Agonists Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Selective Agonists Market Concentration Ratio
  3.2.1 Global Selective Agonists Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Selective Agonists Revenue in 2019
3.3 Selective Agonists Key Players Head office and Area Served
3.4 Key Players Selective Agonists Product Solution and Service
3.5 Date of Enter into Selective Agonists Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Selective Agonists Historic Market Size by Type (2015-2020)
4.2 Global Selective Agonists Forecasted Market Size by Type (2021-2026)

5 SELECTIVE AGONISTS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Selective Agonists Market Size by Application (2015-2020)
5.2 Global Selective Agonists Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Selective Agonists Market Size (2015-2020)
6.2 Selective Agonists Key Players in North America (2019-2020)
6.3 North America Selective Agonists Market Size by Type (2015-2020)
6.4 North America Selective Agonists Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Selective Agonists Market Size (2015-2020)
7.2 Selective Agonists Key Players in Europe (2019-2020)
7.3 Europe Selective Agonists Market Size by Type (2015-2020)
7.4 Europe Selective Agonists Market Size by Application (2015-2020)

8 CHINA

8.1 China Selective Agonists Market Size (2015-2020)
8.2 Selective Agonists Key Players in China (2019-2020)
8.3 China Selective Agonists Market Size by Type (2015-2020)
8.4 China Selective Agonists Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Selective Agonists Market Size (2015-2020)
9.2 Selective Agonists Key Players in Japan (2019-2020)
9.3 Japan Selective Agonists Market Size by Type (2015-2020)
9.4 Japan Selective Agonists Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Selective Agonists Market Size (2015-2020)
10.2 Selective Agonists Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Selective Agonists Market Size by Type (2015-2020)
10.4 Southeast Asia Selective Agonists Market Size by Application (2015-2020)

11 INDIA

11.1 India Selective Agonists Market Size (2015-2020)
11.2 Selective Agonists Key Players in India (2019-2020)
11.3 India Selective Agonists Market Size by Type (2015-2020)
11.4 India Selective Agonists Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Selective Agonists Market Size (2015-2020)
12.2 Selective Agonists Key Players in Central & South America (2019-2020)
12.3 Central & South America Selective Agonists Market Size by Type (2015-2020)
12.4 Central & South America Selective Agonists Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Merck
  13.1.1 Merck Company Details
  13.1.2 Merck Business Overview and Its Total Revenue
  13.1.3 Merck Selective Agonists Introduction
  13.1.4 Merck Revenue in Selective Agonists Business (2015-2020))
  13.1.5 Merck Recent Development
13.2 Bausch Health Companies
  13.2.1 Bausch Health Companies Company Details
  13.2.2 Bausch Health Companies Business Overview and Its Total Revenue
  13.2.3 Bausch Health Companies Selective Agonists Introduction
  13.2.4 Bausch Health Companies Revenue in Selective Agonists Business (2015-2020)
  13.2.5 Bausch Health Companies Recent Development
13.3 Pfizer
  13.3.1 Pfizer Company Details
  13.3.2 Pfizer Business Overview and Its Total Revenue
  13.3.3 Pfizer Selective Agonists Introduction
  13.3.4 Pfizer Revenue in Selective Agonists Business (2015-2020)
  13.3.5 Pfizer Recent Development
13.4 Sterling Winthrop
  13.4.1 Sterling Winthrop Company Details
  13.4.2 Sterling Winthrop Business Overview and Its Total Revenue
  13.4.3 Sterling Winthrop Selective Agonists Introduction
  13.4.4 Sterling Winthrop Revenue in Selective Agonists Business (2015-2020)
  13.4.5 Sterling Winthrop Recent Development
13.5 Sanofi
  13.5.1 Sanofi Company Details
  13.5.2 Sanofi Business Overview and Its Total Revenue
  13.5.3 Sanofi Selective Agonists Introduction
  13.5.4 Sanofi Revenue in Selective Agonists Business (2015-2020)
  13.5.5 Sanofi Recent Development
13.6 Paragon BioTeck
  13.6.1 Paragon BioTeck Company Details
  13.6.2 Paragon BioTeck Business Overview and Its Total Revenue
  13.6.3 Paragon BioTeck Selective Agonists Introduction
  13.6.4 Paragon BioTeck Revenue in Selective Agonists Business (2015-2020)
  13.6.5 Paragon BioTeck Recent Development
13.7 West-Ward Pharmaceuticals
  13.7.1 West-Ward Pharmaceuticals Company Details
  13.7.2 West-Ward Pharmaceuticals Business Overview and Its Total Revenue
  13.7.3 West-Ward Pharmaceuticals Selective Agonists Introduction
  13.7.4 West-Ward Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
  13.7.5 West-Ward Pharmaceuticals Recent Development
13.8 Biosyent Pharma
  13.8.1 Biosyent Pharma Company Details
  13.8.2 Biosyent Pharma Business Overview and Its Total Revenue
  13.8.3 Biosyent Pharma Selective Agonists Introduction
  13.8.4 Biosyent Pharma Revenue in Selective Agonists Business (2015-2020)
  13.8.5 Biosyent Pharma Recent Development
13.9 Novartis
  13.9.1 Novartis Company Details
  13.9.2 Novartis Business Overview and Its Total Revenue
  13.9.3 Novartis Selective Agonists Introduction
  13.9.4 Novartis Revenue in Selective Agonists Business (2015-2020)
  13.9.5 Novartis Recent Development
13.10 Omega Laboratories
  13.10.1 Omega Laboratories Company Details
  13.10.2 Omega Laboratories Business Overview and Its Total Revenue
  13.10.3 Omega Laboratories Selective Agonists Introduction
  13.10.4 Omega Laboratories Revenue in Selective Agonists Business (2015-2020)
  13.10.5 Omega Laboratories Recent Development
13.11 Medical Purchasing Solutions
  10.11.1 Medical Purchasing Solutions Company Details
  10.11.2 Medical Purchasing Solutions Business Overview and Its Total Revenue
  10.11.3 Medical Purchasing Solutions Selective Agonists Introduction
  10.11.4 Medical Purchasing Solutions Revenue in Selective Agonists Business (2015-2020)
  10.11.5 Medical Purchasing Solutions Recent Development
13.12 Avadel Legacy Pharmaceuticals
  10.12.1 Avadel Legacy Pharmaceuticals Company Details
  10.12.2 Avadel Legacy Pharmaceuticals Business Overview and Its Total Revenue
  10.12.3 Avadel Legacy Pharmaceuticals Selective Agonists Introduction
  10.12.4 Avadel Legacy Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
  10.12.5 Avadel Legacy Pharmaceuticals Recent Development
13.13 Amneal Biosciences
  10.13.1 Amneal Biosciences Company Details
  10.13.2 Amneal Biosciences Business Overview and Its Total Revenue
  10.13.3 Amneal Biosciences Selective Agonists Introduction
  10.13.4 Amneal Biosciences Revenue in Selective Agonists Business (2015-2020)
  10.13.5 Amneal Biosciences Recent Development
13.14 Cipla USA
  10.14.1 Cipla USA Company Details
  10.14.2 Cipla USA Business Overview and Its Total Revenue
  10.14.3 Cipla USA Selective Agonists Introduction
  10.14.4 Cipla USA Revenue in Selective Agonists Business (2015-2020)
  10.14.5 Cipla USA Recent Development
13.15 Par Pharmaceutical
  10.15.1 Par Pharmaceutical Company Details
  10.15.2 Par Pharmaceutical Business Overview and Its Total Revenue
  10.15.3 Par Pharmaceutical Selective Agonists Introduction
  10.15.4 Par Pharmaceutical Revenue in Selective Agonists Business (2015-2020)
  10.15.5 Par Pharmaceutical Recent Development
13.16 Glaxosmithkline
  10.16.1 Glaxosmithkline Company Details
  10.16.2 Glaxosmithkline Business Overview and Its Total Revenue
  10.16.3 Glaxosmithkline Selective Agonists Introduction
  10.16.4 Glaxosmithkline Revenue in Selective Agonists Business (2015-2020)
  10.16.5 Glaxosmithkline Recent Development
13.17 Teva
  10.17.1 Teva Company Details
  10.17.2 Teva Business Overview and Its Total Revenue
  10.17.3 Teva Selective Agonists Introduction
  10.17.4 Teva Revenue in Selective Agonists Business (2015-2020)
  10.17.5 Teva Recent Development
13.18 Bayer
  10.18.1 Bayer Company Details
  10.18.2 Bayer Business Overview and Its Total Revenue
  10.18.3 Bayer Selective Agonists Introduction
  10.18.4 Bayer Revenue in Selective Agonists Business (2015-2020)
  10.18.5 Bayer Recent Development
13.19 Impax Generics
  10.19.1 Impax Generics Company Details
  10.19.2 Impax Generics Business Overview and Its Total Revenue
  10.19.3 Impax Generics Selective Agonists Introduction
  10.19.4 Impax Generics Revenue in Selective Agonists Business (2015-2020)
  10.19.5 Impax Generics Recent Development
13.20 Mylan Pharmaceuticals
  10.20.1 Mylan Pharmaceuticals Company Details
  10.20.2 Mylan Pharmaceuticals Business Overview and Its Total Revenue
  10.20.3 Mylan Pharmaceuticals Selective Agonists Introduction
  10.20.4 Mylan Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
  10.20.5 Mylan Pharmaceuticals Recent Development
13.21 Physicians Total Care
  10.21.1 Physicians Total Care Company Details
  10.21.2 Physicians Total Care Business Overview and Its Total Revenue
  10.21.3 Physicians Total Care Selective Agonists Introduction
  10.21.4 Physicians Total Care Revenue in Selective Agonists Business (2015-2020)
  10.21.5 Physicians Total Care Recent Development
13.22 Cadila Pharnmaceuticals
  10.22.1 Cadila Pharnmaceuticals Company Details
  10.22.2 Cadila Pharnmaceuticals Business Overview and Its Total Revenue
  10.22.3 Cadila Pharnmaceuticals Selective Agonists Introduction
  10.22.4 Cadila Pharnmaceuticals Revenue in Selective Agonists Business (2015-2020)
  10.22.5 Cadila Pharnmaceuticals Recent Development
13.23 Alembic Pharmaceuticals
  10.23.1 Alembic Pharmaceuticals Company Details
  10.23.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
  10.23.3 Alembic Pharmaceuticals Selective Agonists Introduction
  10.23.4 Alembic Pharmaceuticals Revenue in Selective Agonists Business (2015-2020)
  10.23.5 Alembic Pharmaceuticals Recent Development
13.24 Allergan
  10.24.1 Allergan Company Details
  10.24.2 Allergan Business Overview and Its Total Revenue
  10.24.3 Allergan Selective Agonists Introduction
  10.24.4 Allergan Revenue in Selective Agonists Business (2015-2020)
  10.24.5 Allergan Recent Development
13.25 Mylan
  10.25.1 Mylan Company Details
  10.25.2 Mylan Business Overview and Its Total Revenue
  10.25.3 Mylan Selective Agonists Introduction
  10.25.4 Mylan Revenue in Selective Agonists Business (2015-2020)
  10.25.5 Mylan Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Selective Agonists Key Market Segments
Table 2. Key Players Covered: Ranking by Selective Agonists Revenue
Table 3. Ranking of Global Top Selective Agonists Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Selective Agonists Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of ?1 Selective Agonists
Table 6. Key Players of ?2 Selective Agonists
Table 7. Key Players of ?1 Selective Agonists
Table 8. Key Players of ?2 Selective Agonists
Table 9. COVID-19 Impact Global Market: (Four Selective Agonists Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Selective Agonists Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Selective Agonists Players to Combat Covid-19 Impact
Table 14. Global Selective Agonists Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Selective Agonists Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Selective Agonists Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Selective Agonists Market Share by Regions (2015-2020)
Table 18. Global Selective Agonists Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Selective Agonists Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Selective Agonists Market Growth Strategy
Table 24. Main Points Interviewed from Key Selective Agonists Players
Table 25. Global Selective Agonists Revenue by Players (2015-2020) (Million US$)
Table 26. Global Selective Agonists Market Share by Players (2015-2020)
Table 27. Global Top Selective Agonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Agonists as of 2019)
Table 28. Global Selective Agonists by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Selective Agonists Product Solution and Service
Table 31. Date of Enter into Selective Agonists Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 34. Global Selective Agonists Market Size Share by Type (2015-2020)
Table 35. Global Selective Agonists Revenue Market Share by Type (2021-2026)
Table 36. Global Selective Agonists Market Size Share by Application (2015-2020)
Table 37. Global Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 38. Global Selective Agonists Market Size Share by Application (2021-2026)
Table 39. North America Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Selective Agonists Market Share (2019-2020)
Table 41. North America Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 42. North America Selective Agonists Market Share by Type (2015-2020)
Table 43. North America Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 44. North America Selective Agonists Market Share by Application (2015-2020)
Table 45. Europe Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Selective Agonists Market Share (2019-2020)
Table 47. Europe Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Selective Agonists Market Share by Type (2015-2020)
Table 49. Europe Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Selective Agonists Market Share by Application (2015-2020)
Table 51. China Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 52. China Key Players Selective Agonists Market Share (2019-2020)
Table 53. China Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 54. China Selective Agonists Market Share by Type (2015-2020)
Table 55. China Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 56. China Selective Agonists Market Share by Application (2015-2020)
Table 57. Japan Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Selective Agonists Market Share (2019-2020)
Table 59. Japan Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Selective Agonists Market Share by Type (2015-2020)
Table 61. Japan Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Selective Agonists Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Selective Agonists Market Share (2019-2020)
Table 65. Southeast Asia Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Selective Agonists Market Share by Type (2015-2020)
Table 67. Southeast Asia Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Selective Agonists Market Share by Application (2015-2020)
Table 69. India Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 70. India Key Players Selective Agonists Market Share (2019-2020)
Table 71. India Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 72. India Selective Agonists Market Share by Type (2015-2020)
Table 73. India Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 74. India Selective Agonists Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Selective Agonists Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Selective Agonists Market Share (2019-2020)
Table 77. Central & South America Selective Agonists Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Selective Agonists Market Share by Type (2015-2020)
Table 79. Central & South America Selective Agonists Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Selective Agonists Market Share by Application (2015-2020)
Table 81. Merck Company Details
Table 82. Merck Business Overview
Table 83. Merck Product
Table 84. Merck Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 85. Merck Recent Development
Table 86. Bausch Health Companies Company Details
Table 87. Bausch Health Companies Business Overview
Table 88. Bausch Health Companies Product
Table 89. Bausch Health Companies Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 90. Bausch Health Companies Recent Development
Table 91. Pfizer Company Details
Table 92. Pfizer Business Overview
Table 93. Pfizer Product
Table 94. Pfizer Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 95. Pfizer Recent Development
Table 96. Sterling Winthrop Company Details
Table 97. Sterling Winthrop Business Overview
Table 98. Sterling Winthrop Product
Table 99. Sterling Winthrop Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 100. Sterling Winthrop Recent Development
Table 101. Sanofi Company Details
Table 102. Sanofi Business Overview
Table 103. Sanofi Product
Table 104. Sanofi Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 105. Sanofi Recent Development
Table 106. Paragon BioTeck Company Details
Table 107. Paragon BioTeck Business Overview
Table 108. Paragon BioTeck Product
Table 109. Paragon BioTeck Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 110. Paragon BioTeck Recent Development
Table 111. West-Ward Pharmaceuticals  Company Details
Table 112. West-Ward Pharmaceuticals  Business Overview
Table 113. West-Ward Pharmaceuticals  Product
Table 114. West-Ward Pharmaceuticals  Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 115. West-Ward Pharmaceuticals  Recent Development
Table 116. Biosyent Pharma  Business Overview
Table 117. Biosyent Pharma  Product
Table 118. Biosyent Pharma  Company Details
Table 119. Biosyent Pharma  Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 120. Biosyent Pharma  Recent Development
Table 121. Novartis Company Details
Table 122. Novartis Business Overview
Table 123. Novartis Product
Table 124. Novartis Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 125. Novartis Recent Development
Table 126. Omega Laboratories Company Details
Table 127. Omega Laboratories Business Overview
Table 128. Omega Laboratories Product
Table 129. Omega Laboratories Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 130. Omega Laboratories Recent Development
Table 131. Medical Purchasing Solutions Company Details
Table 132. Medical Purchasing Solutions Business Overview
Table 133. Medical Purchasing Solutions Product
Table 134. Medical Purchasing Solutions Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 135. Medical Purchasing Solutions Recent Development
Table 136. Avadel Legacy Pharmaceuticals Company Details
Table 137. Avadel Legacy Pharmaceuticals Business Overview
Table 138. Avadel Legacy Pharmaceuticals Product
Table 139. Avadel Legacy Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 140. Avadel Legacy Pharmaceuticals Recent Development
Table 141. Amneal Biosciences Company Details
Table 142. Amneal Biosciences Business Overview
Table 143. Amneal Biosciences Product
Table 144. Amneal Biosciences Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 145. Amneal Biosciences Recent Development
Table 146. Cipla USA Company Details
Table 147. Cipla USA Business Overview
Table 148. Cipla USA Product
Table 149. Cipla USA Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 150. Cipla USA Recent Development
Table 151. Par Pharmaceutical Company Details
Table 152. Par Pharmaceutical Business Overview
Table 153. Par Pharmaceutical Product
Table 154. Par Pharmaceutical Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 155. Par Pharmaceutical Recent Development
Table 156. Glaxosmithkline Company Details
Table 157. Glaxosmithkline Business Overview
Table 158. Glaxosmithkline Product
Table 159. Glaxosmithkline Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 160. Glaxosmithkline Recent Development
Table 161. Teva Company Details
Table 162. Teva Business Overview
Table 163. Teva Product
Table 164. Teva Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 165. Teva Recent Development
Table 166. Bayer Company Details
Table 167. Bayer Business Overview
Table 168. Bayer Product
Table 169. Bayer Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 170. Bayer Recent Development
Table 171. Impax Generics Company Details
Table 172. Impax Generics Business Overview
Table 173. Impax Generics Product
Table 174. Impax Generics Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 175. Impax Generics Recent Development
Table 176. Mylan Pharmaceuticals Company Details
Table 177. Mylan Pharmaceuticals Business Overview
Table 178. Mylan Pharmaceuticals Product
Table 179. Mylan Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 180. Mylan Pharmaceuticals Recent Development
Table 181. Physicians Total Care Company Details
Table 182. Physicians Total Care Business Overview
Table 183. Physicians Total Care Product
Table 184. Physicians Total Care Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 185. Physicians Total Care Recent Development
Table 186. Cadila Pharnmaceuticals Company Details
Table 187. Cadila Pharnmaceuticals Business Overview
Table 188. Cadila Pharnmaceuticals Product
Table 189. Cadila Pharnmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 190. Cadila Pharnmaceuticals Recent Development
Table 191. Alembic Pharmaceuticals Company Details
Table 192. Alembic Pharmaceuticals Business Overview
Table 193. Alembic Pharmaceuticals Product
Table 194. Alembic Pharmaceuticals Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 195. Alembic Pharmaceuticals Recent Development
Table 196. Allergan Company Details
Table 197. Allergan Business Overview
Table 198. Allergan Product
Table 199. Allergan Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 200. Allergan Recent Development
Table 201. Mylan Company Details
Table 202. Mylan Business Overview
Table 203. Mylan Product
Table 204. Mylan Revenue in Selective Agonists Business (2015-2020) (Million US$)
Table 205. Mylan Recent Development
Table 206. Research Programs/Design for This Report
Table 207. Key Data Information from Secondary Sources
Table 208. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Selective Agonists Market Share by Type: 2020 VS 2026
Figure 2. ?1 Selective Agonists Features
Figure 3. ?2 Selective Agonists Features
Figure 4. ?1 Selective Agonists Features
Figure 5. ?2 Selective Agonists Features
Figure 6. Global Selective Agonists Market Share by Application: 2020 VS 2026
Figure 7. Paroxysmal Supraventricular Tachycardia Case Studies
Figure 8. Eye Drops Case Studies
Figure 9. Anaphylaxis Case Studies
Figure 10. Cardiac Arrest Case Studies
Figure 11. Anaphylaxis Case Studies
Figure 12. Cardiac Arrest Case Studies
Figure 13. Chronic Heart Failure Case Studies
Figure 14. Myocardial Infarction Case Studies
Figure 15. Postoperative Hypotension Case Studies
Figure 16. Selective Agonists Report Years Considered
Figure 17. Global Selective Agonists Market Size YoY Growth 2015-2026 (US$ Million)
Figure 18. Global Selective Agonists Market Share by Regions: 2020 VS 2026
Figure 19. Global Selective Agonists Market Share by Regions (2021-2026)
Figure 20. Porter's Five Forces Analysis
Figure 21. Global Selective Agonists Market Share by Players in 2019
Figure 22. Global Top Selective Agonists Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Selective Agonists as of 2019
Figure 23. The Top 10 and 5 Players Market Share by Selective Agonists Revenue in 2019
Figure 24. North America Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Europe Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. China Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Japan Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Southeast Asia Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. India Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. Central & South America Selective Agonists Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Merck Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 33. Bausch Health Companies Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Bausch Health Companies Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 35. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Pfizer Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 37. Sterling Winthrop Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Sterling Winthrop Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 39. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Sanofi Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 41. Paragon BioTeck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Paragon BioTeck Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 43. West-Ward Pharmaceuticals  Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. West-Ward Pharmaceuticals  Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 45. Biosyent Pharma  Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Biosyent Pharma  Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 47. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Novartis Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 49. Omega Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Omega Laboratories Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 51. Medical Purchasing Solutions Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Medical Purchasing Solutions Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 53. Avadel Legacy Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Avadel Legacy Pharmaceuticals Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 55. Amneal Biosciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Amneal Biosciences Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 57. Cipla USA Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Cipla USA Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 59. Par Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Par Pharmaceutical Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 61. Glaxosmithkline Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Glaxosmithkline Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 63. Teva Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. Teva Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 65. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Bayer Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 67. Impax Generics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Impax Generics Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 69. Mylan Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 70. Mylan Pharmaceuticals Revenue Growth Rate in Selective Agonists Business (2015-2020)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed